PTPN11 and myeloproliferative disorder: Recent preclinical studies suggest other interesting potential therapies, such as the protein tyrosine kinase inhibitor dasatinib, which reverts HCM in both NS SHP2-D61G and NSML SHP2-Y279C mice (Yi et al., 2016; Yi et al., 2021), the anti-inflammatory corticosteroid Dexamethasone, which ameliorates the JMML-like MPN in NS Shp2-D61G zebrafish model (Solman et al., 2022), and HDAC inhibitors used in fruitfly (Das et al., 2021).